No Prescription |
 |
 | ||
|
Ural Sachet Citravescent |
|
| ||
No Prescription » Prescription Drugs 16 » Ural Sachet Citravescent Urinary alkaliniser Symptomatic treatment of gastric hyperacidity.Dose:Dissolve 1 Sachet in Cold water 3-4 times daily. Buy Ural Sachet Citravescent and other Prescription Drugs 16 products online at Medstore. 5650
About Ural Sachet Citravescent: Product Type: Prescription Drugs 16 Ural Sachet ( Citravescent Generic Sodium bicarbonate Sodium citrate Citric acid Tartaric acid ) Ural Sachet (Citravescent Generic Sodium bicarbonate Sodium citrate Citric acid Tartaric acid) Citravescent Generic Sodium bicarbonate Sodium citrate Citric acid Tartaric acid 1.76/0.63/0.72/0.89g 28 x 4gm Citravescent Generic Sodium bicarbonate Sodium citrate Citric acid Tartaric acid Ural Sachet
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
